Latest news

PCI Biotech to present at Immunotherapy Forum 2015

Posted on Jan 27, 2015

Lysaker, January 27, 2015 – PCI Biotech announced that the company will be presenting at the Immunotherapy Forum 2015. The forum is hosted by Phacilitate and takes place January 26-28 in Washington, DC, USA. The presentation will be held January 27 local time 11:00 at Grand Hyatt Washington and the company will be represented by […]

PCI Biotech: Successful Investigational New Drug application (IND) review for Amphinex

Posted on Jan 20, 2015

Lysaker, 20 January 2015 – PCI Biotech announces that it has today received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Amphinex. Amphinex is in development as a new local treatment for recurrent head and neck cancer and the phase […]

Fully underwritten rights issue of NOK 70 million – link to prospectus and online subscription

Posted on Jan 20, 2015

The extraordinary general meeting in PCI Biotech Holding ASA (the “Company”) held on 6 January 2015 resolved to conduct a rights issue of 7 million shares in the Company at a subscription price of NOK 10.00 per offer share. Shareholders in the Company, as evidenced in the Company’s shareholders register in the Norwegian Central Securities […]